Characterization of hypoxia response patterns identified prognosis and immunotherapy response in bladder cancer

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492 Morales, 1976, Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors, J. Urol., 116, 180 Meeks, 2020, Genomic heterogeneity in bladder cancer: Challenges and possible solutions to improve outcomes, Nat. Rev. Urol., 17, 259, 10.1038/s41585-020-0304-1 Bhat, 2019, Urinary biomarkers in bladder cancer: Where do we stand?, Curr. Opin. Urol., 29, 203, 10.1097/MOU.0000000000000605 Aine, 2015, On molecular classification of bladder cancer: Out of one, many, Eur. Urol., 68, 921, 10.1016/j.eururo.2015.07.021 Sjödahl, 2012, A molecular taxonomy for urothelial carcinoma, Clin. Cancer Res., 18, 3377, 10.1158/1078-0432.CCR-12-0077-T Damrauer, 2014, Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology, Proc. Natl. Acad. Sci. USA, 111, 3110, 10.1073/pnas.1318376111 Choi, 2014, Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy, Cancer Cell, 25, 152, 10.1016/j.ccr.2014.01.009 2014, Comprehensive molecular characterization of urothelial bladder carcinoma, Nature, 507, 315, 10.1038/nature12965 Hanahan, 2012, Accessories to the crime: Functions of cells recruited to the tumor microenvironment, Cancer Cell, 21, 309, 10.1016/j.ccr.2012.02.022 Gajewski, 2013, Innate and adaptive immune cells in the tumor microenvironment, Nat. Immunol., 14, 1014, 10.1038/ni.2703 Semenza, 2012, Hypoxia-inducible factors in physiology and medicine, Cell, 148, 399, 10.1016/j.cell.2012.01.021 Keith, 2007, Hypoxia-inducible factors, stem cells, and cancer, Cell, 129, 465, 10.1016/j.cell.2007.04.019 Majmundar, 2010, Hypoxia-inducible factors and the response to hypoxic stress, Mol. Cell, 40, 294, 10.1016/j.molcel.2010.09.022 Gilkes, 2014, Hypoxia and the extracellular matrix: Drivers of tumour metastasis, Nat. Rev. Cancer, 14, 430, 10.1038/nrc3726 Semenza, 2010, Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics, Oncogene, 29, 625, 10.1038/onc.2009.441 Jayaprakash, 2018, Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy, J. Clin. Invest., 128, 5137, 10.1172/JCI96268 Jing, 2019, Role of hypoxia in cancer therapy by regulating the tumor microenvironment, Mol. Cancer, 18, 157, 10.1186/s12943-019-1089-9 Vokes, 2018, Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-Year update and outcomes in patients with liver metastases, Ann. Oncol., 29, 959, 10.1093/annonc/mdy041 Sharma, 2017, Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial, Lancet Oncol., 18, 312, 10.1016/S1470-2045(17)30065-7 Larkin, 2018, Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: A randomized, controlled, open-label phase III trial, J. Clin. Oncol., 36, 383, 10.1200/JCO.2016.71.8023 Ho, 2015, Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor t cell responses, Cell, 162, 1217, 10.1016/j.cell.2015.08.012 Barsoum, 2014, A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells, Cancer Res., 74, 665, 10.1158/0008-5472.CAN-13-0992 Chouaib, 2017, Hypoxic stress: Obstacles and opportunities for innovative immunotherapy of cancer, Oncogene, 36, 439, 10.1038/onc.2016.225 Facciabene, 2011, Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells, Nature, 475, 226, 10.1038/nature10169 Noman, 2014, PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation, J. Exp. Med., 211, 781, 10.1084/jem.20131916 Corzo, 2010, HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment, J. Exp. Med., 207, 2439, 10.1084/jem.20100587 Chen, 2017, Elements of cancer immunity and the cancer-immune set point, Nature, 541, 321, 10.1038/nature21349 Qian, 2018, Dendritic cells in the regulation of immunity and inflammation, Semin. Immunol., 35, 3, 10.1016/j.smim.2017.12.002 Kim, 2019, A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma, Int. J. Cancer, 145, 2535, 10.1002/ijc.32531 Knudsen, 2019, Cell cycle and beyond: Exploiting new RB1 controlled mechanisms for cancer therapy, Trends Cancer, 5, 308, 10.1016/j.trecan.2019.03.005 Glaser, 2017, APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response, Oncotarget, 9, 4537, 10.18632/oncotarget.23344 Wu, 2017, Tumor microenvironment and therapeutic response, Cancer Lett., 387, 61, 10.1016/j.canlet.2016.01.043 Sormendi, 2018, Hypoxia pathway proteins as central mediators of metabolism in the tumor cells and their microenvironment, Front. Immunol., 9, 40, 10.3389/fimmu.2018.00040 Casey, 2015, Cancer prevention and therapy through the modulation of the tumor microenvironment, Semin. Cancer Biol., 35, S199, 10.1016/j.semcancer.2015.02.007 Qian, 2019, Hypoxia-induced phenotypes that mediate tumor heterogeneity, Adv. Exp. Med. Biol., 1136, 43, 10.1007/978-3-030-12734-3_3 Salmon, 2012, Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors, J. Clin. Invest., 122, 899, 10.1172/JCI45817 Kim, 2016, Immune escape to PD-L1/PD-1 blockade: Seven steps to success (or failure), Ann. Oncol., 27, 1492, 10.1093/annonc/mdw217 Lowe, 2019, Novel TCR-based biologics: Mobilising T cells to warm “cold” tumours, Cancer Treat. Rev., 77, 35, 10.1016/j.ctrv.2019.06.001 Gajewski, 2015, The next hurdle in cancer immunotherapy: Overcoming the non-T-cell-inflamed tumor microenvironment, Semin. Oncol., 42, 663, 10.1053/j.seminoncol.2015.05.011 Gajewski, 2013, Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment, Curr. Opin. Immunol., 25, 268, 10.1016/j.coi.2013.02.009 Fancello, 2019, Tumor mutational burden quantification from targeted gene panels: Major advancements and challenges, J. Immunother. Cancer, 7, 183, 10.1186/s40425-019-0647-4 Rizvi, 2015, Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 Gibney, 2016, Predictive biomarkers for checkpoint inhibitor-based immunotherapy, Lancet Oncol., 17, e542, 10.1016/S1470-2045(16)30406-5 Mariathasan, 2018, TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells, Nature, 554, 544, 10.1038/nature25501 Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4 Tauriello, 2018, TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis, Nature, 554, 538, 10.1038/nature25492 Gautier, 2004, affy—Analysis of Affymetrix GeneChip data at the probe level, Bioinformatics, 20, 307, 10.1093/bioinformatics/btg405 Wagner, 2012, Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples, Theory Biosci, 131, 281, 10.1007/s12064-012-0162-3 Johnson, 2007, Adjusting batch effects in microarray expression data using empirical Bayes methods, Biostatistics, 8, 118, 10.1093/biostatistics/kxj037 Robertson, 2017, Comprehensive molecular characterization of muscle-invasive bladder cancer, Cell, 171, 540, 10.1016/j.cell.2017.09.007 Cao, 2020, An EMT-related gene signature for the prognosis of human bladder cancer, J. Cell. Mol. Med., 24, 605, 10.1111/jcmm.14767 Colaprico, 2016, TCGAbiolinks: An R/Bioconductor package for integrative analysis of TCGA data, Nucleic Acids Res., 44, e71, 10.1093/nar/gkv1507 Chalmers, 2017, Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med., 9, 34, 10.1186/s13073-017-0424-2 Nidheesh, 2017, An enhanced deterministic K-means clustering algorithm for cancer subtype prediction from gene expression data, Comput. Biol. Med., 91, 213, 10.1016/j.compbiomed.2017.10.014 Monti, 2003, Consensus clustering: A resampling-based method for class discovery and visualization of gene expression microarray data, Mach. Learn., 52, 91, 10.1023/A:1023949509487 Ritchie, 2015, limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res., 43, e47, 10.1093/nar/gkv007 Subramanian, 2005, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. USA, 102, 15545, 10.1073/pnas.0506580102 Bindea, 2013, Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer, Immunity, 39, 782, 10.1016/j.immuni.2013.10.003 Charoentong, 2017, Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade, Cell Rep., 18, 248, 10.1016/j.celrep.2016.12.019 Becht, 2016, Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression, Genome Biol., 17, 218, 10.1186/s13059-016-1070-5 Yu, 2012, clusterProfiler: An R package for comparing biological themes among gene clusters, OMICS, 16, 284, 10.1089/omi.2011.0118 Hänzelmann, 2013, GSVA: Gene set variation analysis for microarray and RNA-seq data, BMC Bioinformatics, 14, 7, 10.1186/1471-2105-14-7 Şenbabaoğlu, 2016, Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures, Genome Biol., 17, 231, 10.1186/s13059-016-1092-z Friedman, 2010, Regularization paths for generalized linear models via coordinate descent, J. Stat. Softw., 33, 1 Iasonos, 2008, How to build and interpret a nomogram for cancer prognosis, J. Clin. Oncol., 26, 1364, 10.1200/JCO.2007.12.9791 Mayakonda, 2018, Maftools: Efficient and comprehensive analysis of somatic variants in cancer, Genome Res., 28, 1747, 10.1101/gr.239244.118 Gu, 2016, Complex heatmaps reveal patterns and correlations in multidimensional genomic data, Bioinformatics, 32, 2847, 10.1093/bioinformatics/btw313